Upstream Bio, Inc. (NasdaqGS: UPB)
Health Care · Biotechnology · US
$7.18
+1.56% today · -60.8% 1Y
Upstream Bio, Inc. (NasdaqGS: UPB) operates in the Biotechnology industry within the Health Care sector. The company is valued at $387.23M and employs 75 people.
Over the last twelve months the share price has lost 60.8%, trading between 5.85 and 33.68.
Tweenvest scores Upstream Bio, Inc. across four factors: quality 30/100, value 48/100. Its strongest factor is value.
UPB price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $387.23M
- Revenue (TTM)
- $3.16M
- P/E
- —
- EPS
- -2.90
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $33.68
- 52-week low
- $5.85
- Avg volume (3M)
- —
- Shares outstanding
- 54.77M
- Employees
- 75
- Next earnings
- —
About Upstream Bio, Inc.
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
- ISIN
- US91678A1079
- Founded
- 2021
- Listed since
- Oct 11, 2024
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.80 | +0.00% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $444.00 | +0.40% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.10 | -0.45% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $551.33 | -0.27% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €903.40 | +2.75% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $155.51 | -2.09% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.